Evercore ISI lowered the firm’s price target on Illumina to $180 from $240 and keeps an Outperform rating on the shares, which the firm removed from its “Tactical Outperform” list, explaining that its prior “new CEO catalyst” thesis “did not work.” The firm made the change as part of a preview ahead of Q3 earnings season for the MedTech, Life Science Tools and Diagnostics group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ILMN:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Illumina price target lowered to $170 from $230 at HSBC
- Illumina put volume heavy and directionally bearish
- Illumina price target lowered to $200 from $225 at Stifel
- Illumina price target lowered to $100 from $150 at Barclays
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue